Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Status:
Completed
Trial end date:
2021-07-28
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that long-term disease-free survival (DFS) in patients with
JMML can be achieved with a treatment of busulfan (BU), cyclophosphamide (CY) and melphalan
(L-PAM) followed by hematopoietic cell transplantation (HCT).